. 2021 May 14;70(3):1–26. doi: 10.15585/mmwr.ss7003a1

TABLE 5. Vaccination coverage estimates using an age-appropriate composite* adult vaccination quality measure and individual component measures, by age group — National Health Interview Survey, United States, 2018.

Characteristic	% (95% CI)
	≥19 yrs	19–49 yrs	50–64 yrs	≥65 yrs
	(n = 25,207)^†	(n = 11,318)^†	(n = 6,592)^†	(n = 7,297)^†
Composite measure
Includes influenza during preceding 12 months
Tdap only^§	13.5 (12.7–14.3)	18.7 (17.4–19.9)	3.9 (3.2–4.8)	11.2 (10.0–12.5)
Td or Tdap^¶	20.2 (19.4–21.0)	25.7 (24.5–26.9)	6.7 (6.0–7.6)	22.6 (21.2–24.0)
Does not include influenza during preceding 12 months
Tdap only**	24.0 (22.9–25.2)	36.9 (35.2–38.6)	4.8 (4.1–5.7)	12.1 (10.9–13.5)
Td or Tdap^††	42.3 (41.3–43.3)	64.5 (63.1–65.8)	8.7 (7.9–9.7)	25.4 (23.9–26.8)
Component measures^§§
Influenza during preceding 12 months	44.7 (43.8–45.6)	34.2 (33.0–35.4)	46.9 (45.3–48.4)	68.8 (67.4–70.1)
Td or Tdap	62.9 (61.8–64.0)	64.5 (63.1–65.8)	62.8 (61.2–64.5)	58.9 (57.2–60.5)
Tdap	31.2 (30.0–32.5)	36.9 (35.2–38.6)	26.0 (24.2–27.9)	22.2 (20.5–24.0)
Herpes zoster^¶¶	24.1 (23.1–25.1)	—	11.5 (10.5–12.5)	39.5 (37.9–41.1)
Pneumococcal***	69.0 (67.5–70.4)	—	—	69.0 (67.5–70.4)

NOTE: An additional table for this figure is available at http://stacks.cdc.gov/view/cdc/105326

Abbreviations: CI = confidence interval; Td = tetanus and diphtheria toxoids vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.

* Estimates using data from the 2018 National Health Interview Survey for age-based composite adult vaccination quality measure for tetanus toxoid-containing, pneumococcal, herpes zoster, and influenza vaccines. Influenza vaccination was measured as receipt during the preceding 12 months, in contrast to Table 1, where influenza vaccination coverage for July 2017–May 2018 was estimated using Kaplan–Meier survival analysis. Td/Tdap vaccination was measured as receipt during the preceding 10 years. Pneumococcal and herpes zoster vaccination were measured as ever receiving at least one dose of either kind of vaccine. Estimates for the composite measures (Source: Shen AK, Williams WW, O'Halloran AC, et al. Promoting adult immunization using population-based data for a composite measure. Am J Prev Med 2018;55:517–23) were calculated to include Tdap vaccine during the preceding 10 years (Method 1) or any tetanus-toxoid containing vaccine during the preceding 10 years (Method 2), and both with and without influenza vaccination during the preceding 12 months. Using Method 1, percent of respondents excluded in vaccination coverage estimation including influenza vaccination was 40.7% overall, ranging from 38.4% in adults aged 19–49 years to 43.1% in adults aged ≥65 years; percent of respondents excluded in vaccination coverage estimation excluding influenza vaccination was 40.6% overall, ranging from 38.2% in adults aged 19–49 years to 43.1% in adults aged ≥65 years.

^† Total unweighted sample size for the overall age group. Denominators for each point estimate vary because persons who did not answer vaccination questions were excluded from analysis.

^§ A composite estimate of overall vaccination coverage among adults aged ≥19 years who received the selected vaccines recommended for their age group: for adults aged 19–49 years, influenza and Tdap vaccines; for adults aged 50–64 years, influenza, Tdap, and herpes zoster vaccines; for adults aged ≥65 years, influenza, Tdap, herpes zoster, and pneumococcal vaccines. Estimates for each age group include adults who have received all of the selected vaccines for that specific age group.

^¶ A composite estimate of overall vaccination coverage among adults aged ≥19 years who received the selected vaccines recommended for their age group: for adults aged 19–49 years, influenza AND Td or Tdap vaccines; for adults aged 50–64 years, influenza, Td or Tdap, and herpes zoster vaccines; for adults aged ≥65 years, influenza, Td or Tdap, herpes zoster, and pneumococcal vaccines. Estimates for each age group include adults who have received all of the selected vaccines for that specific age group.

** A composite estimate of overall vaccination coverage among adults aged ≥19 years who received the selected vaccines recommended for their age group: for adults aged 19–49 years, Tdap vaccines; for adults aged 50–64 years, Tdap and herpes zoster vaccines; for adults aged ≥65 years, Tdap, herpes zoster, and pneumococcal vaccines. Estimates for each age group include adults who have received all of the selected vaccines for that specific age group.

^†† A composite estimate of overall vaccination coverage among adults aged ≥19 years who received the selected vaccines recommended for their age group: for adults aged 19–49 years, Td or Tdap vaccines; for adults aged 50–64 years, Td or Tdap and herpes zoster vaccines; for adults aged ≥65 years, Td or Tdap, herpes zoster, and pneumococcal vaccines. Estimates for each age group include adults who have received all of the selected vaccines for that specific age group.

^§§ Definitions of component measures for Td/Tdap, herpes zoster, and pneumococcal vaccines appear in the footnotes of Tables 2–4. For influenza, respondents were asked if they received an influenza shot or nasal spray during the preceding 12 months.

^¶¶ Herpes zoster vaccination coverage among adults aged ≥50 years.

*** Pneumococcal vaccination coverage among adults aged ≥65 years.